HER2/neu expression in adenoid cystic carcinoma of salivary gland origin:: an immunohistochemical study

被引:31
作者
DOri, S
Vered, M
David, R
Buchner, A [1 ]
机构
[1] Tel Aviv Univ, Dept Oral Pathol, Sch Dent Med, IL-69978 Tel Aviv, Israel
[2] Haemek Med Ctr, Dept Pathol, Afula, Israel
[3] Chaim Sheba Med Ctr, Dept Oral & Maxillofacial Surg, IL-52621 Tel Hashomer, Israel
关键词
adenoid cystic carcinoma; HER2/neu; immunohistochemistry;
D O I
10.1034/j.1600-0714.2002.00017.x
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background: Adenoid cystic carcinoma (ACC) is a malignant tumor of salivary gland origin, which is characterized by a high rate of local recurrence and distant hematogenous metastasis. Despite aggressive surgical treatment and radiotherapy, the patient's long-term prognosis is dismal. Prompted by recent studies on the amplification of the oncogene HER2/neu in salivary gland tumors, we analyzed the immunohistochemical overexpression of HER2/neu in salivary glands ACC. If the tumor exhibits overexpression of HER2/neu, then treating it with the anti-HER2/neu therapeutic agent, Herceptin (Trastuzumab, Genentech, CA), could be considered. Methods: The study comprised of 32 samples of formalin-fixed, paraffin-embedded specimens. All laboratory procedures and scoring criteria were performed according to currently approved FDA methods. Results: HER2/neu overexpression was found in only five (16%) cases. Four cases (13%) scored 1+ and one case (3%) scored 2+. Conclusions: The low prevalence of HER2/neu overexpression in ACC limits the clinical utility of Herceptin therapy for salivary gland ACC.
引用
收藏
页码:463 / 467
页数:5
相关论文
共 30 条
[1]   THE PRODUCT OF THE HUMAN C-ERBB-2 GENE - A 185-KILODALTON GLYCOPROTEIN WITH TYROSINE KINASE-ACTIVITY [J].
AKIYAMA, T ;
SUDO, C ;
OGAWARA, H ;
TOYOSHIMA, K ;
YAMAMOTO, T .
SCIENCE, 1986, 232 (4758) :1644-1646
[2]   Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].
Baselga, J ;
Tripathy, D ;
Mendelsohn, J ;
Baughman, S ;
Benz, CC ;
Dantis, L ;
Sklarin, NT ;
Seidman, AD ;
Hudis, CA ;
Moore, J ;
Rosen, PP ;
Twaddell, T ;
Henderson, IC ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744
[3]  
Cho KJ, 1999, HEAD NECK-J SCI SPEC, V21, P414
[4]  
CLARK GM, 1991, CANCER RES, V51, P944
[5]   Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].
Cobleigh, MA ;
Vogel, CL ;
Tripathy, D ;
Robert, NJ ;
Scholl, S ;
Fehrenbacher, L ;
Wolter, JM ;
Paton, V ;
Shak, S ;
Lieberman, G ;
Slamon, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648
[6]  
Ellis GL., 1996, TUMORS SALIVARY GLAN
[7]  
ELLIS GL, 1996, ATLAS TUMOR PATHOL, P213
[8]   Adenoid cystic carcinoma of the head and neck -: Predictors of morbidity and mortality [J].
Fordice, J ;
Kershaw, C ;
El-Naggar, A ;
Goepfert, H .
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 1999, 125 (02) :149-152
[9]   C-ERBB-2/NEU ONCOGENE AND KI-67 ANALYSIS IN THE ASSESSMENT OF PALATAL SALIVARY-GLAND NEOPLASMS [J].
GIANNONI, C ;
ELNAGGAR, AK ;
ORDONEZ, NG ;
TU, ZN ;
AUSTIN, J ;
LUNA, MA ;
BATSAKIS, JG .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 1995, 112 (03) :391-398
[10]   Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands [J].
Gibbons, MD ;
Manne, U ;
Carroll, WR ;
Peters, GE ;
Weiss, HL ;
Grizzle, WE .
LARYNGOSCOPE, 2001, 111 (08) :1373-1378